No Data
Sansure Biotech to Acquire 100% Stake in Diagnostic Company
0.8 billion yuan investment in growth hormones, Sansure Biotech Inc. aggressively acquires Zhongshan Haiji.
New Trade in A-share Mergers and Acquisitions.
Sansure Biotech Inc. (688289.SH): plans to acquire 100% equity of Zhongshan Haiji.
On January 10, Glonghui announced that Sansure Biotech Inc. (688289.SH) plans to acquire 100% equity of Zhongshan Weiming Haiji Biomedical Co., Ltd. (hereinafter referred to as "Zhongshan Haiji", "target company" or "symbol company") for 807.5 million yuan. After the completion of this Trade, Zhongshan Haiji will become a wholly-owned subsidiary of the company. The symbol company has been engaged in the research and development and production of recombinant gene products and Biological Products, with its main products being human growth hormone (short-acting powder injection, short-acting water injection).
Be Wary Of Sansure Biotech (SHSE:688289) And Its Returns On Capital
CICC Starts Sansure Biotech at Outperform With 25.90 Yuan Price Target
Sansure Biotech Inc. (688289.SH): Granted 1.2412 million restricted stocks to 56 incentive recipients.
On December 16th, Gelonghui reports that Sansure Biotech Inc. (688289.SH) announced that on December 16, 2024, it will hold the second Board of Directors' tenth temporary meeting and the second Supervisory Board's seventh temporary meeting in 2024. The meeting will review and approve the proposal regarding the granting of reserved restricted stocks to the incentive targets of the second phase of the 2023 restricted stock incentive plan, establishing December 16, 2024, as the reserved grant date, with a grant price of 8.55 yuan per share for 1.2412 million shares to 56 incentive targets.
